Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial.
A single masked trial of cyclosporin A 5 mg/kg/day versus monthly 1 g intravenous boluses of cyclophosphamide was conducted among 23 patients with Behçet's syndrome and active, potentially reversible uveitis. The trial was unmasked after a mean of 12 (SD 2) months for the cyclosporin A group (n = 12) and a mean of 10 (SD 3) months for the cyclophosphamide group (n = 11). During the initial 6 months the visual acuity significantly improved (p < 0.001) in the cyclosporin A group whereas this was not observed in the cyclophosphamide group. The subsequent follow-up of patients up to 24 months suggested that the initial improvement in visual acuity with cyclosporin A was not sustained. More extensive and especially long-term studies of cyclosporin A in the uveitis of Behçet's syndrome are warranted.
Ozyazgan
Y
Y
Department of Medicine, Cerrahpaşa Medical Faculty, University of Istanbul, Turkey.
Yurdakul
S
S
Yazici
H
H
Tüzün
B
B
Işçimen
A
A
Tüzün
Y
Y
Aktunç
T
T
Pazarli
H
H
Hamuryudan
V
V
Müftüoğlu
A
A
D000293:Adolescent; D000328:Adult; D001528:Behcet Syndrome / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D016037:Single-Blind Method; D013997:Time Factors; D014792:Visual Acuity
D016572:Cyclosporine; D003520:Cyclophosphamide